"Ferric Compounds" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Inorganic or organic compounds containing trivalent iron.
| Descriptor ID |
D005290
|
| MeSH Number(s) |
D01.490.100 D02.691.550.100
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Ferric Compounds".
Below are MeSH descriptors whose meaning is more specific than "Ferric Compounds".
This graph shows the total number of publications written about "Ferric Compounds" by people in this website by year, and whether "Ferric Compounds" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 1 | 2 |
| 2008 | 1 | 0 | 1 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 2 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 0 | 1 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Ferric Compounds" by people in Profiles.
-
Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis. Am J Nephrol. 2024; 55(2):127-135.
-
Effect of Ziltivekimab on Determinants of Hemoglobin in Patients with CKD Stage 3-5: An Analysis of a Randomized Trial (RESCUE). J Am Soc Nephrol. 2024 01 01; 35(1):74-84.
-
Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence. J Nephrol. 2022 04; 35(3):875-888.
-
A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Drug Saf. 2021 Dec; 20(12):1463-1472.
-
Biogeochemical dynamics and microbial community development under sulfate- and iron-reducing conditions based on electron shuttle amendment. PLoS One. 2021; 16(5):e0251883.
-
Characteristics of Patients Who Achieve Serum Phosphorus Control on Sucroferric Oxyhydroxide or Sevelamer Carbonate: A post hoc Analysis of a Phase 3 Study. Nephron. 2020; 144(9):428-439.
-
Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation. Nephrol Dial Transplant. 2020 06 01; 35(6):946-954.
-
Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients. Nephrol Dial Transplant. 2019 07 01; 34(7):1163-1170.
-
Sucroferric oxyhydroxide for the treatment of hyperphosphatemia. Expert Opin Pharmacother. 2018 Jul; 19(10):1137-1148.
-
Long-term efficacy and safety of sucroferric oxyhydroxide in African American dialysis patients. Hemodial Int. 2018 10; 22(4):480-491.